Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.33
+$0.01 · +0.43%
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Previous close
$2.33
+$0.01 · +0.43%
Regular session · ET · Market data may be delayed.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Day range
Current $2.33
52-week range
Current $2.33
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
40
Bearish
Risk
66
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Day range
Current $2.33
52-week range
Current $2.33
Operating income
Net income
| Metric (CAD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 83.74K CAD | 145.01K CAD | 114.1K CAD | 42.95K CAD |
| Gross profit | — | −83.74K CAD | −145.01K CAD | −114.1K CAD | −42.95K CAD |
| Research and development | 13.91M CAD | 15.66M CAD | 8M CAD | 16.43M CAD | 6.88M CAD |
| Selling, general, and administrative | 11.17M CAD | 9.17M CAD | 9.63M CAD | 6.28M CAD | 5.98M CAD |
| Operating expenses | 25.08M CAD | 24.83M CAD | 17.63M CAD | 22.71M CAD | 12.87M CAD |
| Interest income | 333.42K CAD | 812.07K CAD | 550.12K CAD | 199.62K CAD | 29.64K CAD |
| Interest expense | — | — | — | 510.07K CAD | — |
| Depreciation and amortization | 55.8K CAD | 83.74K CAD | 145.01K CAD | 114.1K CAD | 42.95K CAD |
| Operating income | −25.08M CAD | −24.92M CAD | −17.78M CAD | −22.82M CAD | −12.91M CAD |
| Net income | −44.12M CAD | −23.99M CAD | −22.38M CAD | −20.54M CAD | −12.82M CAD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
